Skip to main content
Top

2024 | OriginalPaper | Hoofdstuk

38. Breast cancer

Auteurs : Mirelle Lagendijk, Dr. Lindy A. M. Santegoets, Linetta B. Koppert

Gepubliceerd in: Textbook of Obstetrics and Gynaecology

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Summary

Worldwide, breast cancer is the most frequently diagnosed cancer. In the Netherlands, 1 in 7 women will be diagnosed with breast cancer at some point during life, corresponding with a cumulative lifetime risk of 12–13 %. Approximately 75 % of the newly diagnosed breast cancer patients are aged 50 or older. Approximately 7 % are less than 40 years. These young women with breast cancer comprise a particular subset due to the often more aggressive biology of their tumours as well as their unique psychosocial concerns. They are at a higher risk of carrying a high-risk allele for hereditary breast cancer and will be offered counselling by a clinical geneticist irrespective of their family history. Young women, who are often advised to have systemic chemotherapy, can be confronted with treatment-related infertility and/or premature ovarian failure. Therefore counselling by gynaecologists, in close collaboration with medical oncologists, is immediately offered after diagnosis if they want to have children in the future. Young women can suffer various other long-term physical and mental side effects of oncological treatment. Problems related to premature ovarian failure include menopausal symptoms such as hot flushes, genitourinary problems, psychological and psychosexual difficulties, and accelerated loss of bone mineral density. Premature menopause may contribute to increased cardiovascular morbidity.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Lagendijk M, Mittendorf E, King TA, Gibbons C, Pusic A, Dominici. Incorporating Patient-Reported Outcome Measurses into Breast Surgical Oncology: Advancing Toward Value-Based Care. Oncologist. 2020;25(5):384–90. Lagendijk M, Mittendorf E, King TA, Gibbons C, Pusic A, Dominici. Incorporating Patient-Reported Outcome Measurses into Breast Surgical Oncology: Advancing Toward Value-Based Care. Oncologist. 2020;25(5):384–90.
2.
go back to reference Boere I, Lok C, Poortmans P, Koppert L, Painter R, Heuvel-eibrink M, Amant F. Breast cancer during Pregnancy: Epidemiology, phenotypes, presentation during Pregnancy and therapeutic modalities. Best Pract Res Clin Onstet Gynaecol. 2022;82:46–59.CrossRef Boere I, Lok C, Poortmans P, Koppert L, Painter R, Heuvel-eibrink M, Amant F. Breast cancer during Pregnancy: Epidemiology, phenotypes, presentation during Pregnancy and therapeutic modalities. Best Pract Res Clin Onstet Gynaecol. 2022;82:46–59.CrossRef
3.
go back to reference Amant F, Von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31(20):2532–9.CrossRefPubMed Amant F, Von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31(20):2532–9.CrossRefPubMed
4.
go back to reference Cardoso F, Veer LJ van’t, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, Van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. (Mindact Investigators) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29. Cardoso F, Veer LJ van’t, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, Van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. (Mindact Investigators) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.
5.
go back to reference Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51. Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.
6.
go back to reference Bartels S, Donker M, Poncet C, Sauve N, Straver M, Van de Velde C, Mansel R, Blanken C, Orzalesi L, Klinkenbijl JHG, Van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp S, van Dalen T, Marinelli A, Rijna H Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Van Tienhoven G, Van Duijnhoven F, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-Year Results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol 2022. Bartels S, Donker M, Poncet C, Sauve N, Straver M, Van de Velde C, Mansel R, Blanken C, Orzalesi L, Klinkenbijl JHG, Van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp S, van Dalen T, Marinelli A, Rijna H Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Van Tienhoven G, Van Duijnhoven F, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-Year Results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol 2022.
7.
go back to reference Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed
8.
go back to reference Giuliano A, Ballman KV, McCall L, Beitsch PD, Brennan MB, Keleman PR, Ollila DW, Hansen NM, Whitworth PA, Blumencranz PW, Leitsch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–926. Giuliano A, Ballman KV, McCall L, Beitsch PD, Brennan MB, Keleman PR, Ollila DW, Hansen NM, Whitworth PA, Blumencranz PW, Leitsch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318(10):918–926.
9.
go back to reference Chlebowski RT, Aragaki AK, Anderson GL, Pan K, Neuhouser M, Manson JE, Thomson CA, Mossavar-Rahmani Y, Lane DS, Johnson KC, Wactawski-WendeJ, Snetselaar L, Rohan TE, Luo J, Narac, Pentice RL; Women's Health Initiative. Dietary modification and breast cancer mortality: Long-term Follow-Up of the Women's Health Initiative Randomized Trial. J Clin Oncol. 2020;38(13):1419–28. Chlebowski RT, Aragaki AK, Anderson GL, Pan K, Neuhouser M, Manson JE, Thomson CA, Mossavar-Rahmani Y, Lane DS, Johnson KC, Wactawski-WendeJ, Snetselaar L, Rohan TE, Luo J, Narac, Pentice RL; Women's Health Initiative. Dietary modification and breast cancer mortality: Long-term Follow-Up of the Women's Health Initiative Randomized Trial. J Clin Oncol. 2020;38(13):1419–28.
10.
go back to reference Heemskerk-Gerritsen BAM, Jager A, Koppert L, Obdeijn AIM, Collee M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, Van Engelen K, De Vries J, Van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning MJ. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723–33.CrossRefPubMedPubMedCentral Heemskerk-Gerritsen BAM, Jager A, Koppert L, Obdeijn AIM, Collee M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, Van Engelen K, De Vries J, Van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning MJ. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723–33.CrossRefPubMedPubMedCentral
11.
go back to reference Sobin LH, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. New York: John Wiley & Sons, Inc.; 2009. Sobin LH, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumors. 7th ed. New York: John Wiley & Sons, Inc.; 2009.
12.
go back to reference Ong WL, Schouwenburg MG, van Bommel ACM, Stowell C, Allison KH, Benn KE, Browne JP, Cooter RD, Delaney GP, Duhoux F, Ganz PA, Hancock P, Jagsi R, Knaul FM, Knip AM, Koppert L, Kuerer H, McLaughin S, Mureau MAM, Partridge A, Purtell Reid D, Sheeran L, Smith TJ, Stoutjesdijk M, Vrancken Peeters MJTFD, Wengstrom Y, Yip CH, Saunders C. A standard set of Value-Based PAteint-Centerd Outcomes for breast cancer: The international Consortium for Heatlh Outcomes Measurement (ICHOM). JAMA Oncol. 2017;3(5):677–85. Ong WL, Schouwenburg MG, van Bommel ACM, Stowell C, Allison KH, Benn KE, Browne JP, Cooter RD, Delaney GP, Duhoux F, Ganz PA, Hancock P, Jagsi R, Knaul FM, Knip AM, Koppert L, Kuerer H, McLaughin S, Mureau MAM, Partridge A, Purtell Reid D, Sheeran L, Smith TJ, Stoutjesdijk M, Vrancken Peeters MJTFD, Wengstrom Y, Yip CH, Saunders C. A standard set of Value-Based PAteint-Centerd Outcomes for breast cancer: The international Consortium for Heatlh Outcomes Measurement (ICHOM). JAMA Oncol. 2017;3(5):677–85.
13.
go back to reference De Ligt KM, De Rooij BH, Hedayati E, Kartsen MM, Smaardijk VR, Velting M, Saunders C, Travado L, Cardoso F, Lopex E, Carney N, Wengstrom Y, Ives A, Velikoca G, Sousa Fialho MDL, Seidler Y, Stamm TA, Koppert L, Van de Poll-Franse LV. International development of a patient-centered core outcome set for assessing heatlh-related quality of life in metastatic breast cancer patients. Breast Cancer Res Treat. 2023 Jan. De Ligt KM, De Rooij BH, Hedayati E, Kartsen MM, Smaardijk VR, Velting M, Saunders C, Travado L, Cardoso F, Lopex E, Carney N, Wengstrom Y, Ives A, Velikoca G, Sousa Fialho MDL, Seidler Y, Stamm TA, Koppert L, Van de Poll-Franse LV. International development of a patient-centered core outcome set for assessing heatlh-related quality of life in metastatic breast cancer patients. Breast Cancer Res Treat. 2023 Jan.
14.
go back to reference Simons J, Van Nijnatten TJA, Van der Pol CC, Van Diest P, Jager A, Van Klaveren D, Kam BLR, Lobbes MBI, De Boer M, Verhoef C, Sars PRA, Heijmans HJ, Van Haaren ERM, Vles WJ, Contant CME, Menke-Puijmers MBE, Smit LHM, Kelder W, Boskamp M, Koppert L, Luiten EJT, Smidt ML. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. JAMA Surg. 2022;157(11):991–9.CrossRefPubMedPubMedCentral Simons J, Van Nijnatten TJA, Van der Pol CC, Van Diest P, Jager A, Van Klaveren D, Kam BLR, Lobbes MBI, De Boer M, Verhoef C, Sars PRA, Heijmans HJ, Van Haaren ERM, Vles WJ, Contant CME, Menke-Puijmers MBE, Smit LHM, Kelder W, Boskamp M, Koppert L, Luiten EJT, Smidt ML. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. JAMA Surg. 2022;157(11):991–9.CrossRefPubMedPubMedCentral
15.
go back to reference Ruddy KJ, Vierkant RA, Jahan N, Higgins A, Partridge A, Larson N, Radisky DC, Couch F, Olson J, Sherman M. Reproductive risk factors associated with breast cancer in young women by molecular subtype. Breast 22; 66; 272–277. Ruddy KJ, Vierkant RA, Jahan N, Higgins A, Partridge A, Larson N, Radisky DC, Couch F, Olson J, Sherman M. Reproductive risk factors associated with breast cancer in young women by molecular subtype. Breast 22; 66; 272–277.
Metagegevens
Titel
Breast cancer
Auteurs
Mirelle Lagendijk
Dr. Lindy A. M. Santegoets
Linetta B. Koppert
Copyright
2024
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2994-6_38